Since KRAS mutation accounts for more than 20% of all NSCLC and RAS is overexpressed in NSCLC patient tissues, we investigated the effect of KYA1797K, a small molecule which had an anti-cancer effect in CRC via degrading both β-catenin and Ras14, in KRAS mutated NSCLC. This evidence concerns the gene KRAS and cancer.